Thanks to a handful of initial public offerings (IPOs) in the last year, individual investors can now own liquid biopsy stocks. Thanks to awful performance last month, most of them are trading at their lowest levels in months -- or ever. Shares of Adaptive Biotechnologies (NASDAQ: ADPT) f...

Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...

Investors should be cautious when a business relies too heavily on a single customer. If the relationship changes or ends, then it's usually not very fun to be a shareholder. It can take years for the company and stock to recover -- if a recovery can be achieved at all. That's what makes the hi...